TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female ≥ 18 years of age at the time of signing the informed consent form (ICF).~2. Clinical diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) (initial or recurrent), which included thrombocytopenia and microscopic evidence of red blood cell fragmentation (e.g., schistocytes).~3. Required initiation of daily PE treatment and had received 1 PE treatment prior to randomization~4. Others as defined in the protocol~Exclusion Criteria:~1. Platelet count ≥100×10E9/L.~2. Serum creatinine level \>200 µmol/L in case platelet count is \> 30×10E9/L~3. Known other causes of thrombocytopenia~4. Congenital TTP (known at the time of study entry).~5. Pregnancy or breast-feeding.~6. Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown~7. Others as defined in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caplacizumab (Type: EXPERIMENTAL): Caplacizumab 10 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed diagnosis of non-anaplastic non-medullary thyroid cancer that is either grossly recurrent after surgery or unresectable with or without metastatic disease.~* Age ≥18 years~* Karnofsky performance status ≥70%~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months after treatment.~* Patients must have ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Women who are pregnant or lactating~* Inability to comply with study and/or follow-up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMRT and doxorubicin (Type: EXPERIMENTAL): All patients will undergo radiation treatments using IMRT with concurrent low-dose radiosensitizing doxorubicin at 10 mg/m2 will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* normal weight women with Polycystic ovary syndrome, diagnosed in accordance with Rotterdam Consensus Conference Criteria 2003.~Exclusion Criteria:~* pregnancy~* past history of cardiovascular disease, diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral glucose tolerance test), hypertension~* significant liver or renal impairment~* other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs)~* neoplasms~* unstable mental illness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 3 mg drospirenone and 20 µg ethinyl-estradiol (Type: ACTIVE_COMPARATOR): None
- 3 mg drospirenone and 30 µg ethinyl-estradiol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe scalp Seborrheic Dermatitis~Exclusion Criteria:~* Subjects suffering from psoriasis,~* Subjects with a known allergy to one of the components of the test products,~* Female subjects who are pregnant, nursing or planning a pregnancy during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C propionate 4/week + Ketoconasole 2/week (Type: EXPERIMENTAL): Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
- C propionate 2/week + Ketoconasole 2/week (Type: EXPERIMENTAL): Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
- C propionate 2/week (Type: EXPERIMENTAL): Clobetasol propionate shampoo 0.05% (2/week)
- Ketoconazole 2/week (Type: ACTIVE_COMPARATOR): Ketoconazole shampoo 2% (2/week)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan Versus Enalapril in Heart Failure With Reduced Ejection Fraction Patients With Moderately Impaired Kidney Functions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 80 years~* Patients with signs and/or symptoms of heart failure NYHA II, III or IV, with echocardiographic diagnosis of HFrEF..~* Moderate impairment of renal functions, assessed by measuring serum creatinine levels then estimating the glomerular filtration rate (eGFR) by Cockroft-Gold equation to be (60-40 ml/min/m2).~Exclusion Criteria:~* Refusal to participate in the study.~* Known allergy to enalapril/telmisartan components.~* Pregnant and lactating ladies.~* Severe renal impairment defined as eGFR\<30ml/min/m2 at time of enrollment to the study.~* Known cases of bilateral severe renal artery stenosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Telmisartan (Type: ACTIVE_COMPARATOR): Telmisartan (20 up to 80mg) for RAAS inhibition, as part of their heart failure therapy.
- Enalapril (Type: NO_INTERVENTION): Enalapril (2.5 up to 20mg ) for RAAS inhibition, as part of their heart failure therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel in Node Positive Adjuvant Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven breast cancer (invasive adenocarcinoma with at least one axillary lymph node showing evidence of tumor among a minimum of six resected lymph nodes).~* Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection for operable breast cancer. Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma.~Exclusion criteria:~* Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).~* Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TAC (Docetaxel) (Type: EXPERIMENTAL): docetaxel (75 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment
- FAC (5-fluorouracil) (Type: ACTIVE_COMPARATOR): 5-fluorouracil (500 mg/m\^2) in combination with doxorubicin (50 mg/m\^2) and cyclophosphamide (500 mg/m\^2) on day 1 every 3 weeks for 6 cycles of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, or signet cell or small cell features;~* Presence of bone metastatic disease as assessed by at least two lesions on whole body metastable technetium-methylene diphosphonate (99mTc-MDP) bone scintigraphy;~* Throughout the study, ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone (LHRH) analogue or prior bilateral orchiectomy (medical or surgical castration);~* Testosterone ≤ 1.73 nmol/L (≤ 50 ng/dL) at screening;~* Progressive disease on androgen deprivation therapy at screening defined as a minimum of two sequentially rising prostate-specific antigen (PSA) values (PSA1 \< PSA2 \< PSA3);~* The screening PSA (PSA3) must be ≥ 2 μg/L (≥ 2 ng/mL).~Exclusion Criteria:~* Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra 223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the CRPC setting for the treatment of prostate cancer or participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless treatment was placebo);~* Treatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy) within 4 weeks before enrollment;~* Initiation of new treatment with denosumab, bisphosphonates, or systemic corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;~* Use of an investigational agent within 4 weeks before the screening visit;~* Radiation therapy to bone within 4 weeks before enrollment;~* Use of opiate analgesics for prostate cancer pain within 4 weeks before enrollment;~* Screening 99mTc-MDP bone scintigraphy showing a superscan;~* Visceral (eg, lung, liver) metastatic disease. Adenopathy is allowed;~* Current or previously treated brain metastasis or active leptomeningeal disease;~* History of seizure any time in the past for any reason or any condition that may predispose to seizures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide monotherapy (Type: EXPERIMENTAL): Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive using the bioMerieux (bMx) investigational use only (IUO) THxID BRAF Assay (IDE: G120011). The assay will be conducted by a central reference laboratory. Subjects with ocular or mucosal melanoma are not eligible.~* The subject must have a radiologically measurable tumor~* The subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).~* Able to swallow and retain oral medication~* Sexually active subjects must use acceptable methods of contraception during the course of the study~* Adequate organ system function and blood counts~Exclusion Criteria:~* Prior treatment with a BRAF or a MEK inhibitor~* Prior systemic anti-cancer treatment for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma. Prior systemic treatment in the adjuvant setting is allowed. (Note: Ipilimumab treatment must end at least 8 weeks prior to randomization.)~* The subject has received major surgery or certain tyes of cancer therapy with 21 days of starting treatment~* Current use of prohibited medication listed in the protocol~* Left ventricular ejection fraction less than the lower limit of normal~* Uncontrolled blood pressurl~* History or current evidence of retinal vein occlusion or central serous retinopathy~* Brain metastases unless previously treated with surgery or stereotactic radiosurgery and the disease has been stable for at least 12 weeks~* The subject is pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib + Trametinib (Type: EXPERIMENTAL): Dabrafenib and Trametinib combination
- Dabrafenib + Placebo (Type: ACTIVE_COMPARATOR): Dabrafenib and Trametinib placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eletriptan Pharmacokinetics In Korean Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male subjects, 18-55 years old~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2~* provide informed consent~Exclusion Criteria:~* blood pressure \>140/90 mm Hg~* any condition possibly affecting drug absorption~* positive urine drug screen

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): 1 X 20 mg eletriptan
- Treatment B (Type: EXPERIMENTAL): 1 X 40 mg eletriptan
- Treatment C (Type: EXPERIMENTAL): 2 X 40 mg eletriptan
- Treatment D (Type: EXPERIMENTAL): 1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic renal cell carcinoma, histopathologically confirmed~* Treated with sunitinib according to Smpc~* For cases: Achieving a CR (local assessment according to RECIST V1.0 criteria) with Sunitinib in prior 6 months alone OR in combination with local treatment (surgery, radiation therapy, ablative techniques: cryotherapy, RFA)~* For controls: Life expectancy \> 3 months No prior Sunitinib treatment~* Patient \>18 years~Exclusion Criteria:~* Sunitinib administered in a non-approved label~* For cases: CR occurring without sunitinib treatment~* For controls: Prior systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Complete Remission (Type: None): Complete remission arm in mRCC patients treated with sunitinib.
- Non Complete Remission (Type: None): Non complete remission arm in mRCC patients treated with sunitinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:- Male and female patients aged 18 years or above- Patients scheduled for elective total knee replacement Exclusion Criteria:- Active bleeding or high risk of bleeding contraindicating treatment with LMWH- Contraindication listed in the labeling or conditions precluding subject treatment with enoxaparin or requiring dose adjustment (e.g. severe renal impairment, please refer to the local label of enoxaparin in your country)- Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Young Parents Program, Project Connect

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to speak and read in English~* Mothers must be 18 or under when baby is born~* Fathers must be 25 or under when baby is born~* Child must be seen in YPP~* Willing to complete computer surveys 6 times over 36 months~* Ability to complete computer assisted data collection~Exclusion Criteria:~* If parent does not have custody of children~* If children are no longer receiving care at YPP

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Young Parents Program plus Parenting/Life Skills modules (Type: EXPERIMENTAL): In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
- Young Parents Program usual care (Type: ACTIVE_COMPARATOR): Patients receive regular standard of care without modules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of PROGRESSive Training and Teststerone in Older Frail Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Living in their own home or in sheltered accommodation. Independent gait possible. with tool. Capable of stand-up and sit in a chair at least 8 times in 30 sec. There must be at least 3 symptoms or objective findings of low testosterone . Serum testosterone \<10nmol /L as the average of two independent measurements~-~Exclusion Criteria:~Known or previous prostate cancer. Abnormally elevated serum PSA (PSA = prostate specific antigen) corresponding to PSA\> 5 ng / ml or PSA\> 0.15 ng / ml / cc (relative to the prostatic volume in cubic centimeters (cc)). Hæmatomacrose. Heart disease in the form of: peri-, myo-, or endocarditis, angina, severe heart failure (NYHA class III and IV), severe hypertension (systolic blood pressure\> 180 or diastolic BT\> 105 mmHg after antihypertensive therapy). Dyspnoea at rest. Liver (AST\> 2 x ULN) or renal impairment (serum creatinine\> 200 micromoles / L). Severe and insufficiently treated epilepsy or migraine. Insulin treatment. Previous or current bifosfonat-, fluoride, HRT, SERM-, strontium, teraparatid- or more than 3 weeks of prednisolone. Joint disease with acute inflammation. Active cancer disease in chemo- or radiotherapy. Bone metabolic disease apart from age-related osteoporosis. Autoimmune diseases, chronic systemic diseases (cirrhosis, AIDS, chronic renal failure). Primary testosterone deficiency in the form of testicular dysgenesis, Klinefelter syndrome (47, XXY), 46, XX males, LH-resistance, the Y chromosome deletions, other sex chromosome abnormalities ,. Significant abuse, mental illness, dementia, physical disability with inability to implement intervention or tests or to give informed consent. Contraindications to testosterone undecanoate is included in the exclusion criteria, such as. presence of liver tumors, breast and prostate cancer, as subjects will be examined before the trial starts.

- Gender: MALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Controls (Type: NO_INTERVENTION): A control group, which is 20 weeks with placebo injections without training.
- Testosterone (Type: EXPERIMENTAL): A testosterone group given 20 weeks on testosterone injections without training
- Training (Type: EXPERIMENTAL): A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
- Testosterone and training (Type: EXPERIMENTAL): A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete